title: Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group.
abstract: The 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group was held on the 20th-21st October 2016 in Munich. This second Summit was organized in light of recently published CVOTs on diabetes, with the aim of serving as a reference meeting for discussion on this topic. Along with presentations on the results of the most recently published CVOTs, panel discussions on trial implications for reimbursement and the perspective of cardiologists and/or nephrologists, as well as on CVOTs weaknesses and potentials constituted the heart of the program. Future activities of the D&CVD EASD Study Group in 2017 include an annual meeting in Milano and the 3rd CVOT Summit on Diabetes of the D&CVD EASD Study Group, in Munich ( http://www.dcvd.org ).
authors.affiliation: Forschergruppe Diabetes e.V., Munich, Ingolstaedter Landstrasse 1, 85764, Neuherberg, Germany. oliver.schnell@lrz.uni-muenchen.de
authors.forename: Oliver
authors.initials: O
authors.lastname: Schnell
authors.affiliation: Forschergruppe Diabetes e.V., Munich, Ingolstaedter Landstrasse 1, 85764, Neuherberg, Germany. oliver.schnell@lrz.uni-muenchen.de
authors.forename: Eberhard
authors.initials: E
authors.lastname: Standl
authors.affiliation: Internal Medicine Department, Clinical County Emergency Hospital Constanta, Tomis Blvd, No. 145, 900591 Constanta, Romania.
authors.forename: Doina
authors.initials: D
authors.lastname: Catrinoiu
authors.affiliation: Diabetes and Metabolic Disease Unit, IRCCS MultiMedica, Via Milanese 300, 20099 Sesto San Giovanni, MI Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Genovese
authors.affiliation: Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Dr Subotica 13, Belgrade, 11000 Serbia.
authors.forename: Nebojsa
authors.initials: N
authors.lastname: Lalic
authors.affiliation: 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, U Nemocnice 1, 128 08 Prague 2, Czech Republic.
authors.forename: Jan
authors.initials: J
authors.lastname: Skra
authors.affiliation: Department of Endocrinology Diabetology Nutrition, CINFO, CRNH-IdF, Jean VERDIER Hospital, Paris 13 University, Avenue du 14 Juillet, 93140 Bondy, France.
authors.forename: Paul
authors.initials: P
authors.lastname: Valensi
authors.affiliation: Diabetes and Metabolic Disorders, Dubrava University Hospital, Avenija Gojka Šuška 6, 10000 Zagreb, Croatia.
authors.forename: Dario
authors.initials: D
authors.lastname: Rahelic
authors.affiliation: Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigacion Biomèdica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Barcelona, Spain.|Department of Cardiovascular and Metabolic Diseases, IRCCS Multimedica, Sesto San Giovanni, Milan, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Ceriello
mesh_terms: D002318:Cardiovascular Diseases / Q000191:economics / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000191:economics / Q000401:mortality; D016527:Drug Costs; D019317:Evidence-Based Medicine; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D007349:Insurance, Health, Reimbursement; D065840:Protective Factors; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents